One of the biggest moments at the annual meeting of the American Society of Clinical Oncology last month came when a drug investigator from M.D. Anderson Cancer Center presented explained that a recent clinical trial for the drug Avastin had left doctors "with no more clarity" about how to treat brain cancer patients than they had before the trial, according to the New York Times.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.